Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes

IL-22, cell regeneration and autoimmunity

(2015) Enayat Nikoopour et al.   CYTOKINE

FactoMineR: AnRPackage for Multivariate Analysis

(2015) Sébastien Lê et al.   Journal of Statistical Software

Reduction in CD4 Central Memory T-Cell Subset in Costimulation Modulator Abatacept-Treated Patients With Recent-Onset Type 1 Diabetes Is Associated With Slower C-Peptide Decline

(2014) T. Orban et al.   DIABETES

Delayed Anti-CD3 Therapy Results in Depletion of Alloreactive T Cells and the Dominance of Foxp3+CD4+Graft Infiltrating Cells

(2013) R. Goto et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

(2013) K. C. Herold et al.   DIABETES

Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes: Two-Year Results From the Randomized, Placebo-Controlled Protege Trial

(2013) W. Hagopian et al.   DIABETES

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

(2013) Mark R Rigby et al.   Lancet Diabetes & Endocrinology

Induction of Allograft Tolerance by Monoclonal CD3 Antibodies: A Matter of Timing

(2012) S. You et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial

(2012) K. C. Herold et al.   DIABETOLOGIA

Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients

(2012) Ken T. Coppieters et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Teplizumab Induces Human Gut-Tropic Regulatory Cells in Humanized Mice and Patients

(2012) F. Waldron-Lynch et al.   Science Translational Medicine

Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6

(2011) Wenda Gao et al.   CELL CYCLE

An Allele ofIKZF1(Ikaros) Conferring Susceptibility to Childhood Acute Lymphoblastic Leukemia Protects Against Type 1 Diabetes

(2011) Austin D.-E. Swafford et al.   DIABETES

Peripheral and Islet Interleukin-17 Pathway Activation Characterizes Human Autoimmune Diabetes and Promotes Cytokine-Mediated  -Cell Death

(2011) S. Arif et al.   DIABETES

NKG2A is a marker for acquisition of regulatory function by human CD8+T cells activated with anti-CD3 antibody

(2011) Vitaly Ablamunits et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

(2011) Nicole Sherry et al.   LANCET

Control of TH17 cells occurs in the small intestine

(2011) Enric Esplugues et al.   NATURE

Acquisition of regulatory function by human CD8+ T cells treated with anti-CD3 antibody requires TNF

(2010) Vitaly Ablamunits et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients

(2009) B. Keymeulen et al.   BLOOD

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years

(2009) Kevan C. Herold et al.   CLINICAL IMMUNOLOGY

Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies

(2009) Simona Cernea et al.   CLINICAL IMMUNOLOGY